Loading stock data…
GeneDx Holdings Corp. (WGS)
$69.12-0.70 (-1.00%)
Market ClosedLast close Jun 29
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeneDx Holdings Corp. in the Healthcare sector is trading at $69.12 with a market capitalization of $1.6B. Wall Street consensus targets $78.44 (9 analysts), implying a +13.5% move over the next 12 months. The stock is currently 60% below its 52-week high of $170.87, remaining 29.1% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 71 is overbought against a weak tape. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +13.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 71 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $102.25M↓ | $120.99M↑ | $116.74M↑ | $102.69M↑ | $87.11M |
| Gross Profit | $68.21M↓ | $84.27M↓ | $84.53M↑ | $70.90M↑ | $58.48M |
| Operating Income | -$26.18M↓ | -$14.23M↓ | -$3.25M↓ | $8.96M↑ | -$4.55M |
| Net Income | -$63.32M↓ | -$17.67M↓ | -$7.63M↓ | $10.81M↑ | -$6.53M |
Peer Comparison
JNJUNHPFE
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.62%
Volume
Today's trading volume
1.01M
Recent News
What a $227,000 GeneDx Insider Sale Means as Revenue Climbs 17%
GeneDx leverages AI-driven analytics for healthcare insights; a key insider recently trimmed their stake, according to SEC filings.
Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
GeneDx Holdings, known for AI-driven health data, reported a notable insider buy amid continued momentum in precision medicine services.
GeneDx Holdings (WGS) Valuation After Q1 2026 Earnings Miss Guidance Cut And Legal Scrutiny
Q1 shock, guidance cut and legal actions put GeneDx Holdings (WGS) under scrutiny GeneDx Holdings (WGS) has been in focus after a substantial Q1 2026 earnings miss, a much higher net loss, a 12% cut to full year revenue guidance and a large Fabric Genomics impairment. These financial updates, combined with multiple securities law firms launching investigations and class action lawsuits over alleged misstatements, have contributed to sharp recent volatility in GeneDx Holdings stock. See our...
From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading
Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.